Table 2 Twelve-month diagnosis of 425 patients presenting with unilateral pleural effusion between 2008 and 2013 and the median and interquartile range of serum procalcitonin, white cell count and C-reactive protein
From: The role of serum procalcitonin in establishing the diagnosis and prognosis of pleural infection
Diagnosis | n | % | Procalcitonin (μg/l) | White cell count (×109/L) | C-reactive protein (mg/l) |
|---|---|---|---|---|---|
Metastatic malignancy | 169 | 39.8% | <0.05 (0–0.12) | 8.9 (7.4–11.0) | 34.5 (12–90.75) |
Pleural infection | 80 | 18.8% | 0.2 (0.1–0.7) | 12.5 (9.2–16.3) | 135.3 (71.6–239.6) |
Malignant mesothelioma | 70 | 16.5% | <0.05 (<0.05- < 0.05) | 8.7 (7.1–9.7) | 22.2 (9.5–70.3) |
Congestive cardiac failure | 41 | 9.6% | <0.05 (<0.05–0.1) | 7.4 (6.2–9.2) | 9.0 (5.1–22.6) |
BAPE | 17 | 4.0% | <0.05 (<0.05–0.1) | 8.5 (7.5–9.4) | 27.0 (15.4–53.0) |
Inflammatory pleuritis | 13 | 3.1% | <0.05 (<0.05–0.1) | 7.1 (6.3–7.9) | 10.0 (5.0–48.0) |
Pleural TB | 10 | 2.4% | 0.1 (<0.05–0.2) | 7.1 (6.9–7.5) | 76.5 (36.9–111.7) |
Renal failure | 6 | 1.4% | 0.1 (0.1–0.2) | 6.8 (5.8–10.3) | 25.0 (20.8–37.3) |
Hepatic hydrothorax | 4 | 0.9% | <0.05 (<0.05–0.1) | 5.0 (4.2–7.5) | 2.0 (2.0–4.7) |
Pulmonary embolism | 3 | 0.7% | <0.05 (n/a) | 5.8 (n/a) | 14.0 (n/a) |
Iatrogenic/Trauma | 3 | 0.7% | <0.05 (n/a) | 10.4 (n/a) | 32 (n/a) |
Connective tissue disease | 3 | 0.7% | <0.05 (n/a) | 9.0 (n/a) | 29.0 (n/a) |
Post-CABG | 3 | 0.7% | <0.05 (n/a) | 7.6 (n/a) | 3.0 (n/a) |
Pancreatitis | 2 | 0.5% | <0.05 (n/a) | 4.0 (n/a) | 19.0 (n/a) |
Drug-induced | 1 | 0.2% | <0.05 (n/a) | 8.6 (n/a) | 13 (n/a) |